LeMaitre Vascular (NASDAQ:LMAT) Now Covered by Wells Fargo & Company

Research analysts at Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) in a report issued on Thursday, MarketBeat.com reports. The firm set an "equal weight" rating and a $95.00 price target on the medical instruments supplier's stock. Wells Fargo & Company's price objective suggests a potential downside of 3.70% from the stock's previous close.

LMAT has been the subject of several other research reports. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. Finally, Oppenheimer restated an "outperform" rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $94.63.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT traded up $1.66 during mid-day trading on Thursday, hitting $98.65. The company had a trading volume of 223,618 shares, compared to its average volume of 127,390. LeMaitre Vascular has a 12 month low of $59.87 and a 12 month high of $109.58. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of 53.91, a PEG ratio of 2.19 and a beta of 0.96. The firm's 50 day simple moving average is $95.94 and its two-hundred day simple moving average is $93.66.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Townsquare Capital LLC grew its stake in shares of LeMaitre Vascular by 38.0% in the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier's stock worth $4,454,000 after purchasing an additional 13,210 shares during the last quarter. Barclays PLC boosted its holdings in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after buying an additional 29,180 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in LeMaitre Vascular by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock worth $17,789,000 after buying an additional 11,395 shares during the last quarter. Creative Planning increased its holdings in shares of LeMaitre Vascular by 20.7% in the third quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier's stock valued at $334,000 after buying an additional 617 shares in the last quarter. Finally, Copeland Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock valued at $108,068,000 after buying an additional 11,318 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.